Filing Details

Accession Number:
0001209191-17-041631
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-06-23 16:04:32
Reporting Period:
2017-06-21
Filing Date:
2017-06-23
Accepted Time:
2017-06-23 16:04:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
816284 Celgene Corp CELG Pharmaceutical Preparations (2834) 222711928
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1298083 A Michael Friedman C/O Celgene Corporation
86 Morris Avenue
Summit NJ 07901
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-06-21 5,000 $59.06 5,000 No 4 M Direct
Common Stock Disposition 2017-06-21 5,000 $130.00 0 No 4 S Direct
Common Stock Acquisiton 2017-06-22 5,000 $59.06 5,000 No 4 M Direct
Common Stock Disposition 2017-06-22 5,000 $135.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Disposition 2017-06-21 5,000 $0.00 5,000 $59.06
Common Stock Common Stock Disposition 2017-06-22 5,000 $0.00 5,000 $59.06
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
8,600 2023-06-12 No 4 M Direct
3,600 2023-06-12 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 14,907 Indirect Family Trust
Footnotes
  1. These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan.
  2. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  3. The option was fully exercisable.
  4. The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated as of April 15, 2015)).